ReAlta Life Sciences, Inc.: ReAlta Life Sciences Announces P

Presenting proof-of-mechanism clinical trial data in healthy volunteers of RLS-0071, the Company's dual action complement inhibitor and innate anti-inflammatory product candidate ReAlta Life Sciences

Related Keywords

United States , Washington , Germany , Norfolk , Virginia , American , Jensm Hohlfeld , Olaf Holz , Jessica Goss , Linda Dell , Kenji Cunnion , Ulrich Thienel , Philipp Badorrek , Saskia Carstensen , John Rickman , Topics In Airway , Fraunhofer Institute For Toxicology , European Medicines Agency , Drug Administration , Realta Life Sciences Inc , Airway Research , American Thoracic Society , Realta Life Sciences , Waltere Washington Convention Center , Malta Life Sciences , Division Director , Fraunhofer Institute , Experimental Medicine , Novel Dual Targeting Anti Inflammatory Agent , Demonstrates Proof , Significantly Reducing Lung Neutrophils , Pam Hair , Convention Center , Lower Level , Alveolar Epithelial Cell Biology , Orphan Drug Designation , Investor Contact , Financial Officer , Realta , Life , Ciences , Nnounces , Poster , Presentation , Thoracic , Society , 023 , Nnual , Meeting ,